Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento now has exclusive rights in 60% of the world ..."to utilize Dyadic’s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic’s lead COVID-19 vaccine candidate."
Quite apart from the vaccine DYAI-100, the C1 technology can be applied across Sorrento's entire Covid portfolio. It will greatly reduce costs. For example, Sorrento could now have not only the world's BEST COVID ANTIBODIES but also the world's MOST AFFORDABLE! We know that even now, because they are so powerful, they require only small doses. They can be delivered in 2 minute injections rather than 4 hour infusions. They can be delivered in small nasal drops. They can be delivered in small amounts utilizing the SOFUSA technology. Add to that substantial production cost savings using the C1 technology and Sorrento will have enormous pricing advantages which health systems like!